PubRank

A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)

Clinical Trial ID NCT01456325

PubWeight™ 34.56‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01456325

Top papers

Rank Title Journal Year PubWeight™‹?›
1 MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012 1.71
2 Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets 2012 1.45
3 Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res 2014 1.33
4 Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res 2015 1.29
5 Randomized phase II trial designs with biomarkers. J Clin Oncol 2012 1.26
6 Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther 2013 1.22
7 The impact of genomic changes on treatment of lung cancer. Am J Respir Crit Care Med 2013 1.18
8 Antibodies to watch in 2016. MAbs 2015 1.17
9 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
10 Antibodies to watch in 2014. MAbs 2013 1.14
11 The evolving genomic classification of lung cancer. J Pathol 2014 1.08
12 EGFR-TKI resistance in NSCLC patients: mechanisms and strategies. Am J Cancer Res 2014 1.08
13 High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer 2013 1.06
14 Treatment of Non-small Cell Lung Carcinoma after Failure of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. Cancer Res Treat 2013 1.05
15 Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Semin Oncol 2013 1.03
16 The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist 2013 0.98
17 Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol 2015 0.97
18 Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors. Onco Targets Ther 2014 0.97
19 Novel agents in development for advanced non-small cell lung cancer. Ther Adv Med Oncol 2014 0.95
20 Non-Small Cell Lung Cancer beyond Biomarkers: The Evolving Landscape of Clinical Trial Design. J Pers Med 2014 0.92
21 Personalizing therapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2013 0.89
22 Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol 2015 0.87
23 Targeted therapies in non-small cell lung carcinoma: what have we achieved so far? Ther Adv Med Oncol 2013 0.86
24 Targeting genomic alterations in squamous cell lung cancer. Front Oncol 2013 0.85
25 Expression and clinical significance of c-Met in advanced esophageal squamous cell carcinoma. BMC Cancer 2015 0.84
26 Second-Line Therapy for Advanced NSCLC. Oncologist 2013 0.84
27 Emerging options for the management of non-small cell lung cancer. Clin Med Insights Oncol 2013 0.82
28 MET inhibition in lung cancer. Transl Lung Cancer Res 2013 0.82
29 Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance. Cancer Med 2015 0.81
30 Understanding and Targeting MET Signaling in Solid Tumors - Are We There Yet? J Cancer 2016 0.79
31 MET inhibitors in combination with other therapies in non-small cell lung cancer. Transl Lung Cancer Res 2012 0.78
32 Safety of Onartuzumab in Patients with Solid Tumors: Experience to Date from the Onartuzumab Clinical Trial Program. PLoS One 2015 0.78
33 Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. Eur J Cardiothorac Surg 2015 0.77
34 Customised, Individualised Treatment of Metastatic Non-Small-Cell Lung Carcinoma (NSCLC). Sultan Qaboos Univ Med J 2013 0.76
35 Low EGFR/MET ratio is associated with resistance to EGFR inhibitors in non-small cell lung cancer. Oncotarget 2015 0.76
Next 100